Drug-labels.com

Sodium Sulamyd 10% Product Monograph

The product monograph is written for health professionals. Plain-language information for patients is in the patient medication information: pregnancy and breastfeeding.

Status:
Prescription (Rx) Current status: Cancelled Post Market Facts
Strength:
100 mg
Active ingredient:
Similar drugs:

Product Monograph - Sodium Sulamyd 10%

ADVERSE REACTIONS

Sodium sulfacetamide may cause local irritation. Most often the reactions result from allergic sensitization. Although sensitivity reactions to sodium sulfacetamide are rare, instances of Stevens-Johnson syndrome and systemic lupus erythematosus (in one case producing a fatal outcome) have been reported following the use of ophthalmic sulfonamide preparations.

OVERDOSAGE INFORMATION

A single overdose of ophthalmic sodium sulfacetamide would not be expected to produce symptoms.

DOSAGE

10% Solution with Methylcellulose: 1 or 2 drops into the lower conjunctival sac every 2 or 3 hours during the day and less often at night.

SUPPLIED

Each mL of sterile ophthalmic solution contains: sulfacetamide sodium USP 100 mg (10% with methylcellulose USP). Nonmedicinal ingredients: hydroxypropyl methylcellulose, methylparaben, monobasic sodium phosphate, propylparaben, sodium thiosulfate and water. Plastic dropper bottles of 15 mL. Store between 2 and 30°C. Protect from light.

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 00028053

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Sodium Sulamyd 10%

Rx or OTC
Prescription (Rx)?
DIN 00028053
Schedule(s) PRESCRIPTION
Active ingredient(s) Sulfacetamide sodium 100 MG
Dosage form(s) Drops
Route(s) of administration Ophthalmic
Drug class (WHO ATC)
  1. S Sensory organ drugs
    1. S01 Ophthalmologicals
      1. S01A Antiinfective ophthalmologics
        1. S01AB Sulfonamides, ophthalmologic antiinfectives
          1. S01AB04 Sulfacetamide
Company SANDOZ CANADA INCORPORATED
Current status Cancelled Post Market
Current status date August 1, 2018

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.